Last reviewed · How we verify
Xenetix
At a glance
| Generic name | Xenetix |
|---|---|
| Sponsor | Guerbet |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Computed Tomography Vs. Endoscopy Study
- Low-contrast Dose Liver CT Using Lean Body Weight Low Monoenergetic Images and Deep Learning-based Reconstruction (NA)
- Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy (NA)
- Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis (PHASE4)
- Hepatic Xenetix-CT Perfusion (PHASE4)
- Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (PHASE4)
- Contrast-inDuced nephRotoxicity as Assessed by the KIdney Load-to-DAmage RElationship (EARLY_PHASE1)
- A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |